Category Archives: Market Access
By Ben Comer | Published: February 5, 2013
Good science can’t be rushed, even when the lives of patients hang in the balance. But regulatory science, and its relationship to a drug’s commercial success or failure, can inadvertently block access to individual patients in their hour of need.
By Clark Herman | Published: January 30, 2013
In the arcane world of patent litigation, the term ‘pay for delay’ can be misleading, and as the Washington debate to restrict these deals unfolds, it is becoming apparent that a ban on such settlements may serve to delay generics even further. Is the fresh grass of reform really always greener than the well-seeded status [...]
By Jill Wechsler | Published: January 24, 2013
A new international agreement to reduce mercury contamination of air and water was recently adopted by 140 countries, without a proposal that threatened to limit access to vaccines in much of the world. The credit goes to public health authorities and medical experts who challenged a provision blocking production of vaccines with the preservative thimerosal, [...]
By Clark Herman | Published: January 15, 2013
A survey of 600 patient groups worldwide conducted in late 2012 revealed that perceptions of the pharmaceutical industry soured in the past year, mainly due to issues of access, pricing, patient safety and transparency. The Corporate Reputation of Pharma in 2012—the Patient Perspective compared the reputations of 29 leading pharma companies around six different [...]
By Julian Upton | Published: January 2, 2013
In its new study on pharma market growth in Africa, IMS Health highlights three ‘rising star’ countries from the continent’s sub-Saharan region.